Triptorelin

Source high-purity Triptorelin, a potent synthetic GnRH agonist peptide for advanced pharmaceutical and research applications. This critical active ingredient effectively regulates hormonal pathways, making it essential for treating hormone-dependent conditions and supporting reproductive health studies. Ideal for manufacturers of injectable formulations and controlled-release systems. High-quality raw material. Get a quote today!

Product Specification

• Product Name: Triptorelin (Pharmaceutical/Research Grade)
• Appearance: White to off-white lyophilized powder
• CAS No.: 57773-63-4
• Molecular Formula: C₆₄H₈₂N₁₈O₁₃
• Specification: Purity ≥98.5% (HPLC); Molecular Weight: ~1311.5 g/mol; Acetate Content: <5.0%; Water Content: <5.0%; Single Impurity: <0.5%
• Ingredient Information: Synthetic decapeptide analog of Gonadotropin-Releasing Hormone (GnRH); Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂; Soluble in water and acetic acid solutions

Product Description

Triptorelin is a sophisticated synthetic analog of natural gonadotropin-releasing hormone (GnRH), engineered with a substitution of D-tryptophan at position 6 to enhance metabolic stability and receptor binding affinity. Initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), continuous administration leads to the downregulation of GnRH receptors, resulting in a profound suppression of sex steroid production. This biphasic mechanism makes it a cornerstone therapy for managing hormone-sensitive conditions such as prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. Its proven efficacy and established safety profile drive consistent demand in the global pharmaceutical market for both immediate-release and long-acting depot formulations.

Product Uses

This ingredient is primarily utilized in the manufacturing of prescription pharmaceuticals for endocrine disorders. It is the key active component in injectable solutions and microsphere depot formulations designed for the treatment of advanced prostate cancer, where androgen deprivation is critical. Additionally, Triptorelin is extensively used in gynecological therapies for managing endometriosis and uterine leiomyomas by inducing a temporary menopausal state. In pediatric endocrinology, it is formulated for the treatment of central precocious puberty to halt premature sexual development. Beyond clinical use, it serves as a vital reference standard in biomedical research investigating hypothalamic-pituitary-gonadal axis regulation and reproductive biology.

Formulation Recommendation

Recommended Usage Level: Clinical dosages vary significantly by indication and formulation type (e.g., 0.1 mg daily for immediate release vs. 3.75 mg or 11.25 mg monthly/quarterly for depot forms). For R&D, stock solutions are typically prepared at 1–10 mg/mL.
Addition Method: Reconstitute lyophilized powder with sterile water for injection or appropriate buffer (e.g., acetate buffer pH 4–5) immediately before use. For depot formulations, encapsulate within biodegradable polymers like PLGA using emulsion-solvent evaporation techniques. Ensure aseptic processing throughout.
Compatibility: Compatible with standard pharmaceutical excipients such as mannitol, carboxymethylcellulose, and polylactic-co-glycolic acid (PLGA). Avoid exposure to strong oxidizing agents or extreme pH levels (<2 or >10) which may degrade the peptide bond. Store lyophilized product at 2–8°C; protect reconstituted solutions from light and use within specified timeframes to prevent hydrolysis.